Journal of Yeungnam Medical Science

Yeungnam University College of Medicine, Yeungnam University Institute Medical Science (영남대 의대 학술지 편집위원회)
권호 표지
DOI QR코드

DOI QR Code

Secondary amyloidosis complication of Crohn disease treated with infliximab

크론병에 동반된 속발성 아밀로이드증에서 infliximab 치료

  • Song, Min-Joo (Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Kim, Hyo Sang (Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Park, Soyoung (Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Cheon, Jaekyung (Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Park, Sojung (Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Yang, Ji-Young (Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Park, Su-Kil (Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine)
  • 송민주 (울산대학교 의과대학 서울아산병원 내과학교실) ;
  • 김효상 (울산대학교 의과대학 서울아산병원 내과학교실) ;
  • 박소영 (울산대학교 의과대학 서울아산병원 내과학교실) ;
  • 천재경 (울산대학교 의과대학 서울아산병원 내과학교실) ;
  • 박소정 (울산대학교 의과대학 서울아산병원 내과학교실) ;
  • 양지영 (울산대학교 의과대학 서울아산병원 내과학교실) ;
  • 박수길 (울산대학교 의과대학 서울아산병원 내과학교실)
  • Received : 2014.07.01
  • Accepted : 2014.08.18
  • Published : 2015.12.31
Download PDF
⟨ Previous Next ⟩

Abstract

Secondary systemic (AA) amyloidosis is a severe complication of progressed Crohn disease (CD) characterized by the deposition of amyloid A in body organs and tissues. Various therapeutic approaches have been recommended, however there is still no effective treatment. Recently, several case reports have demonstrated the effects of anti-tumor necrosis factor-${\alpha}$ therapy in patients with AA amyloidosis associated with CD. We report on a 35-year-old female patient with CD complicated by AA amyloidosis in the gastrointestinal tract and renal involvement, who was treated with infliximab. The infliximab therapy improved the gastrointestinal symptoms and decreased the serum creatinine.

Keywords